•
Sep 30, 2020
Aytu BioScience Q1 2021 Earnings Report
Aytu BioScience's Q1 2021 financial results were announced, featuring a significant revenue increase and a reduced EBITDA loss.
Key Takeaways
Aytu BioScience reported a substantial increase in net revenue for Q1 2021, reaching $13.5 million, an 839% increase year-over-year. The company reduced its adjusted EBITDA loss to $1.3 million and holds $38.2 million in cash and cash equivalents.
Net revenue increased by 839% year-over-year to $13.5 million.
Consumer Health net revenue reached an all-time high of $7.8 million.
Rx net revenue was $5.8 million, compared to $1.4 million in Q1 last year.
Net loss was $4.3 million, and adjusted EBITDA loss was $1.3 million.
Aytu BioScience
Aytu BioScience
Forward Guidance
The company has strong momentum to maximize shareholder value moving ahead in fiscal 2021 and beyond.